Opal Therapeutics Secures $1.25M NSF SBIR Phase II Award to Accelerate Women’s Health Drug Discovery

Opal Therapeutics secured a $1.25M NSF SBIR Phase II award to scale its uterine organoid platform for endometriosis and fibroid drug discovery. The funding milestone supports ongoing R&D progress, though the amount is unlikely to be material for broader market repricing.

Analysis

Opal Therapeutics secured a $1.25M NSF SBIR Phase II award to scale its uterine organoid platform for endometriosis and fibroid drug discovery. The funding milestone supports ongoing R&D progress, though the amount is unlikely to be material for broader market repricing.